Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 468 of the 468 references it cites were found in a registry or an index.

Wnt/β-catenin signaling in cancers and targeted therapies

Open access
Yu, Fanyuan, Yu, Changhao, Li, Feifei, Zuo, Yanqin, Wang, Yitian, Yao, Lin, Wu, Chenzhou, Wang, Chenglin, Ye, Ling·2021·Signal Transduction and Targeted Therapy

Abstract

Wnt/β-catenin signaling has been broadly implicated in human cancers and experimental cancer models of animals. Aberrant activation of Wnt/β-catenin signaling is tightly linked with the increment of prevalence, advancement of malignant progression, development of poor prognostics, and even ascendence of the cancer-associated mortality. Early experimental investigations have proposed the theoretical potential that efficient repression of this signaling might provide promising therapeutic choices in managing various types of cancers. Up to date, many therapies targeting Wnt/β-catenin signaling in cancers have been developed, which is assumed to endow clinicians with new opportunities of developing more satisfactory and precise remedies for cancer patients with aberrant Wnt/β-catenin signaling. However, current facts indicate that the clinical translations of Wnt/β-catenin signaling-dependent targeted therapies have faced un-neglectable crises and challenges. Therefore, in this study, we systematically reviewed the most updated knowledge of Wnt/β-catenin signaling in cancers and relatively targeted therapies to generate a clearer and more accurate awareness of both the developmental stage and underlying limitations of Wnt/β-catenin-targeted therapies in cancers. Insights of this study will help readers better understand the roles of Wnt/β-catenin signaling in cancers and provide insights to acknowledge the current opportunities and challenges of targeting this signaling in cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-021-00701-5

Cites

468 of 468 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The extracellular components and signaling transduction of Wnt/β-catenin signaling. In this figure, we do not distinguish the autocrine or paracrine patterns of Wnt ligands
Fig. 1 The extracellular components and signaling transduction of Wnt/β-catenin signaling. In this figure, we do not distinguish the autocrine or paracrine patterns of Wnt ligandsCC BY · PubMed Central
Fig. 2 The membrane-linked components and signaling transduction of Wnt/β-catenin signaling. Ub ubiquitin, ① the switch-on of Fzd/Lrp ubiquitination, ② the switch-ff of Fzd/Lrp ubiquitination via Rspo function
Fig. 2 The membrane-linked components and signaling transduction of Wnt/β-catenin signaling. Ub ubiquitin, ① the switch-on of Fzd/Lrp ubiquitination, ② the switch-ff of Fzd/Lrp ubiquitination via Rspo functionCC BY · PubMed Central
Fig. 3 The intracellular components and signaling transduction of Wnt/β-catenin signaling
Fig. 3 The intracellular components and signaling transduction of Wnt/β-catenin signalingCC BY · PubMed Central
Fig. 4 The structural illustration of human β-catenin protein. In this figure we mainly demonstrated the important PPI binding domains and phosphorylation sites of β-catenin. This image was modified from a published research.372
Fig. 4 The structural illustration of human β-catenin protein. In this figure we mainly demonstrated the important PPI binding domains and phosphorylation sites of β-catenin. This image was modified from a published research.372CC BY · PubMed Central
Fig. 5 The statistical summary of up-to-date registered clinical trials of targeted therapies via targeting Wnt/β-catenin signaling in cancers. The left panel indicated the stages and the right one showed the phases of clinical trials. P1 phase I, P1b phase IB, P2 phase 2. All clinical trials included were updated until May 2021
Fig. 5 The statistical summary of up-to-date registered clinical trials of targeted therapies via targeting Wnt/β-catenin signaling in cancers. The left panel indicated the stages and the right one showed the phases of clinical trials. P1 phase I, P1b phase IB, P2 phase 2. All clinical trials included were updated until May 2021CC BY · PubMed Central
Fig. 6 The overview of status quo registered clinical trials of Wnt/β-catenin signaling-dependent targeted therapies in cancers (updated in May 2021). Within the boxed diagram, the first lane provided the numbers of clinical trials for the specific type of cancers in all clinical trials. From the second to the fifth lane, we provided the types of drugs as SMIs, mAbs, Peptides, and others, and the parts that follow the colon indicted the names of drugs and the targeted components of Wnt/β-catenin signaling were shown in the brackets
Fig. 6 The overview of status quo registered clinical trials of Wnt/β-catenin signaling-dependent targeted therapies in cancers (updated in May 2021). Within the boxed diagram, the first lane provided the numbers of clinical trials for the specific type of cancers in all clinical trials. From the second to the fifth lane, we provided the types of drugs as SMIs, mAbs, Peptides, and others, and the parts that follow the colon indicted the names of drugs and the targeted components of Wnt/β-catenin signaling were shown in the bracketsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

4 retracted

Show all 468 references

Research works printed but not linked: 2

  1. Schwarz-Romond, T. The DIX domain of Dishevelled confers Wnt signaling by dynamic polymerization. Nat. Struct. Mol. Biol. 14, 484–492 (2007). · DOI · Paper page
  2. Hoey, T. (ed.) Development of FZD8-Fc (OMP-54 F28), aWnt signaling antagonist that inhibits tumor growth and reduces tumor initiating cell frequency. Presented at AACR Annual Meeting; 2013 April; Washington DC (2013).

Cited by

See all 781

Metadata

Authors
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L.
Affiliations
Sichuan University (CN)
Corresponding author
Ye, Ling
Venue
Signal Transduction and Targeted Therapy
Published
2021-08-30
Volume
6
Issue
1
Pages
307-307
ISSN
2059-3635 (ISSN-L)
OpenAlex
W3198051187
Cited by
734
References
468
Citations by year
2026: 106 · 2025: 234 · 2024: 200 · 2023: 139 · 2022: 53 · 2021: 2
FWCI
10.57
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81825005)
  • State Key Laboratory of Oral Disease
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords
Wnt/β-catenin signaling, cancer, targeted therapy, aberrant signaling, malignant progression, prognosis, clinical translation, treatment resistance
MeSH terms
Humans, Neoplasm Proteins, Neoplasms, Wnt Proteins, beta Catenin, Wnt Signaling Pathway

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Wnt/β-catenin signaling in cancers and targeted therapies. https://app.cochat.ai/papers/10.1038/s41392-021-00701-5
The paper
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021). Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-021-00701-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.